Sign Out
Methotrexate: Intravenous cytarabine given concomitantly with intrathecal methotrexate may increase the risk of severe neurological adverse reactions such as headache, paralysis, coma and stroke like episodes (see Precautions).
Cytarabine has been reported to inhibit the cellular uptake of methotrexate, thus reducing its effectiveness. Conversely, methotrexate has been reported to reduce the cellular activity of cytarabine. These factors should be taken into consideration if the two drugs are used concomitantly.
Digoxin: Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyldigoxin and chemotherapy regimens containing cyclophosphamide, vincristine and prednisone with or without cytarabine or procarbazine. Steady-state plasma digitoxin concentrations did not appear to change. Therefore, monitoring of plasma digoxin levels may be indicated in patients receiving similar combination chemotherapy regimens. The utilization of digitoxin for such patients may be considered as an alternative.
Gentamicin: An in vitro interaction study between gentamicin and cytarabine showed a cytarabine related antagonism for the susceptibility of K. pneumoniae strains. This study suggests that in patients on cytarabine being treated with gentamicin for a K. pneumoniae infection, the lack of a prompt therapeutic response may indicate the need for re-evaluation of antibacterial therapy.
Fluorocytosine: Clinical evidence in one patient showed possible inhibition of fluorocytosine efficacy therapy with cytarabine. This may be due to potential competitive inhibition of its uptake.
